Kempharm Stock Valuation

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Do you want to know what the current value of Kempharm is today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Kempharm, is its stock price multiplied by the total number of shares outstanding, calculating Kempharm's enterprise value requires a different approach. It uses Kempharm's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Kempharm Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 114.02 Million. The current Tangible Asset Value is estimated to increase to about 11.5 M, while Free Cash Flow is projected to decrease to (2.1 M).
Kempharm secures a last-minute Real Value of $13.1 per share. The latest price of the firm is $10.75. At this time, the firm appears to be undervalued. Our model forecasts the value of Kempharm from analyzing the firm fundamentals such as Current Valuation of 328.5 M, profit margin of (74.21) %, and Return On Equity of (222.16) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.

Search Valuation 

 
Refresh
Kempharm Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Kempharm's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
10.75
29th of July 2021
Share
Please note that Kempharm's price fluctuation is somewhat reliable at this time. Calculation of the real value of Kempharm is based on 3 months time horizon. Increasing Kempharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Kempharm is useful when determining the fair value of the Kempharm stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Kempharm. Since Kempharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kempharm Stock. However, Kempharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
13.10
Real Value
16.68
Upside
Estimating the potential upside or downside of Kempharm helps investors to forecast how Kempharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kempharm more accurately as focusing exclusively on Kempharm's fundamentals will not take into account other important factors:
Earnings
Estimates (2)
LowProjected EPSHigh
0.610.620.64
Details
Hype
Prediction
LowEstimated ValueHigh
7.1010.6814.26
Details
2 Analysts
Consensus
LowTarget PriceHigh
10.0019.0028.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. Some money managers use Kempharm's intrinsic value based on its ongoing forecasts of Kempharm's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by look to relative valuation against Kempharm's closest peers. When choosing a valuation method Kempharm, make sure it is appropriate for the firm given its current financial situation and market classification. If more than one is valuation category is appropriate, we suggest using both methods to arrive at a better estimate.

Kempharm Investments

3.01 MillionShare

Kempharm Valuation Drivers Correlation

Many accounts on the financial statements of Kempharm are highly interrelated and sometimes correlated. Consequently, when conducting Kempharm's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Kempharm
Click cells to compare fundamentals

Kempharm Market Cap

Kempharm is rated fifth overall in market capitalization category among related companies. Market capitalization of Biotechnology industry is now estimated at about 9.82 Billion. Kempharm holds roughly 306.74 Million in market capitalization claiming about 3% of stocks in Biotechnology industry.
Capitalization  Valuation  Workforce  Revenue  Total debt

Kempharm Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Kempharm's current stock value. Our valuation model uses many indicators to compare Kempharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kempharm competition to find correlations between indicators driving Kempharm's intrinsic value. More Info.
Kempharm is rated fourth overall in price to earning category among related companies. It is rated fourth overall in price to book category among related companies . . Price to Book Value is estimated to decrease to -0.82

About Kempharm Valuation

The equity valuation mechanism determines the current worth of Kempharm on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Kempharm. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kempharm based exclusively on its fundamental and basic technical indicators. By analyzing Kempharm's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Kempharm's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kempharm. We calculate exposure to Kempharm's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kempharm's related companies.
Last ReportedProjected for 2021
Gross Profit13.3 M14.6 M
Profit Margin(0.96) (1.04) 
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Kempharm Quarterly Enterprise Value

327.09 MillionShare

Kempharm Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Kempharm does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio20.58
Revenue Growth480.00%
Enterprise Value To Ebitda60.96
Enterprise Value To Revenue14.09

Kempharm Current Valuation Indicators

Valuation refers to the process of determining the present value of Kempharm and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kempharm we look at many different elements of the entity such as Kempharm's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.